Group 1 - The company announced a capital increase agreement approved by the board on May 28, 2025, involving investments of RMB 150 million, RMB 130 million, and RMB 20 million from the company, Guangzhou Pharmaceutical Venture Capital Fund, and Guangzhou Old Brand Fund respectively [1] - After the capital increase, the registered capital of Baiyunshan Biological will rise from RMB 84 million to RMB 121 million, while the company's direct and indirect shareholding will remain unchanged at 50% [1] - Baiyunshan Biological is a significant subsidiary of the company, primarily engaged in the research, production, and sales of human rabies vaccines (Vero cells), which is crucial for the company's innovation-driven development strategy [2] Group 2 - The capital increase aims to address the funding needs of Baiyunshan Biological, facilitating the application for production licenses for new products and supporting the development of the company's biopharmaceutical business [2] - Baiyunshan Biological's financial performance will continue to be included in the company's consolidated financial statements [1][2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：00874） 須予披露的交易：出售應收賬款 本次交易 於2025年5月28日，廣州醫藥與興證資管根據基礎資產買賣協議（第四期）簽訂《新增基礎資產交割 確認函》，確認向興證資管出售第三次新增基礎資產，並收到購買價款人民幣401,493,434.77元。 上市規則的含義 然而，根據上市規則第14.22條，如一連串交易全部均於12個月內完成或屬彼此相關者，則該等交 易應合併計算，並視作一項交易處理。鑒於本次交易及過往交易均由廣州醫藥與興證資管於12個 月內訂立，並且交易性質相似，就計算相關百分比率而言，該等交易應根據上市規則第14.22條進 行合併。 由於根據上市規則第14.07條就本次交易及過往交易按合併基準計算的最高適用百分比率高於5% 但低於25%，因此，本次交易構成本公司在上市規則第14章下的須予披露的交易，須遵守上市規 則下的申報及公告規定 ...

Group 1 - The "bottle-to-electric" policy is transforming traditional cooking methods in Guangdong, with many businesses adopting electric cooking appliances for safety and cost efficiency [1][2] - In the first four months of 2025, Guangdong's power grid achieved an electricity substitution of 150.16 billion kilowatt-hours, resulting in a CO2 reduction of 1,497,130 tons, equivalent to planting 818 million trees [1] - The "bottle-to-electric" initiative is supported by a one-stop electricity service, including installation and after-sales support, to facilitate the transition for users [2] Group 2 - As of May 20, 2023, Guangdong's power grid operates 16,242 charging piles across 1,033 towns, enhancing the accessibility of electric vehicles in rural areas [3] - The Guangdong power grid is promoting energy-efficient and low-carbon equipment across various industries, including agriculture and manufacturing, to improve operational efficiency and reduce costs [4][5] - The goal for the year is to achieve an electricity substitution of no less than 410 billion kilowatt-hours, supporting high-quality economic development in Guangdong [6]

Core Insights - The health nutrition industry is undergoing structural transformation due to heightened health awareness, stricter regulations, and a return to rational consumption, leading brands to adjust pricing, optimize inventory, and focus on channel and profit model reconstruction [1][2]. Industry Overview - The health nutrition industry is entering a high-quality development phase in 2024, driven by policy, economic, capital, and technological synergies [10]. - Regulatory bodies are enhancing the registration and filing standards for health nutrition products, increasing oversight across production and sales [11]. Product Category Situation - The industry is focusing on four core consumer groups: middle-aged working individuals, high-net-worth individuals, rehabilitation needs, and the elderly [52]. - Key product categories gaining attention include immune enhancement, joint and bone care, and probiotics, while categories like anti-aging are experiencing a decline [54][56]. Financing Trends - In 2024, the number of financing events in the health nutrition industry decreased, but the total financing amount increased, with upstream companies, particularly probiotic suppliers, being favored by investors [16][17]. - The financing amount rose by 3.21 billion yuan despite a reduction in the number of financing events [18]. Sales Channel Dynamics - Private domain e-commerce has surpassed traditional pharmaceutical chains for the first time, with platforms like Douyin Global Purchase emerging as significant players in the cross-border B2C market [2][30]. - Retailers are increasingly adopting a "direct procurement" model, with over 25% of retailers sourcing products directly from manufacturers [31]. Strategic Adjustments - In response to market pressures, 60% of small and medium-sized enterprises are reducing R&D investments and shifting towards OEM models to maintain cash flow [27]. - Major brands are enhancing their channel, product, and marketing strategies, focusing on dual strategies of high-end and affordable products [26]. Consumer Preferences - The average transaction price for core products in the health nutrition sector has significantly decreased, with 31% of companies reporting prices in the 50-100 yuan range in 2024, up 17.22% from 2023 [14][15]. - The demand for personalized and functional health products is rising, particularly among younger consumers and new parents [81][84]. Future Outlook - By 2025, nearly 42% of companies anticipate that tightening policies and consumer downgrade will hinder rapid growth in the industry [35]. - Brands are expected to shift their focus towards value-driven strategies, including price adjustments and new channel explorations, to sustain growth [37][41].

Core Viewpoint - The article emphasizes the increasing prevalence of stroke among the population aged 40 and above in China, highlighting the importance of early detection, intervention, and treatment to mitigate the risks associated with stroke [1][2]. Group 1: Stroke Statistics and Risk Factors - As of 2023, there are 12.42 million stroke patients aged 40 and above in China, with one person experiencing a stroke every 10 seconds and one person dying from a stroke every 28 seconds [1]. - The top three risk factors for stroke are hypertension (35.62%), dyslipidemia (34.71%), and smoking (31.37%), with physical inactivity at 27.83% [1]. - Common lifestyle habits such as being overweight, staying up late, and consuming a high-fat diet are contributing to the younger onset of stroke [1]. Group 2: Prevention and Awareness Initiatives - In response to the "early detection, early intervention, early treatment" philosophy, a public awareness campaign was held on May 24, 2023, by Guangzhou Baiyunshan Zhongyi Pharmaceutical and Baiyunshan Qixing Pharmaceutical, along with various chain pharmacies across multiple cities [1]. - The campaign aims to educate the public about stroke risks and promote early screening and intervention strategies [3]. Group 3: Medical Insights and Recommendations - Medical professionals stress the importance of recognizing warning signs of stroke, such as facial drooping, sudden speech difficulties, and unilateral weakness [2]. - Immediate action, such as calling emergency services within 4.5 hours of symptoms, is crucial for effective treatment [2]. - Regular monitoring of health indicators for individuals with hypertension, diabetes, and dyslipidemia is recommended, along with lifestyle modifications like smoking cessation and weight control [2][3].

Core Points - The annual shareholder meeting of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. is scheduled for June 3, 2025, at 10:00 AM [6] - The company reported a total operating income of 74.99 billion yuan for 2024, a decrease of 0.69% year-on-year [9][21] - The total profit for the year was 3.61 billion yuan, down 29.41% compared to the previous year [9][29] - The net profit attributable to shareholders was 2.83 billion yuan, a decline of 30.09% year-on-year [9][29] - The company plans to distribute a cash dividend of 0.40 yuan per share, totaling approximately 650 million yuan [35] Meeting Procedures - The meeting will combine online and on-site voting, with a total of 13 resolutions to be voted on, all requiring a simple majority for approval [5][7] - Shareholders must present valid identification and relevant documents to participate in the meeting [4][6] - The results of the voting will be announced after the meeting, combining both online and on-site votes [6][8] Financial Performance - The company faced challenges in 2024 due to insufficient effective demand, industry changes, and increased competition, leading to a decline in major business segments [9][29] - The main business revenue from the traditional Chinese medicine segment decreased by 10.40% to 9.76 billion yuan [21][22] - The gross profit margin for the main business was reported at 16.57%, a decrease from the previous year [21][23] Governance and Compliance - The board of directors held 21 meetings and reviewed 74 proposals, ensuring compliance with relevant laws and regulations [10][12] - The supervisory board conducted five meetings and monitored the company's compliance with governance standards [18][19] - The company has made efforts to enhance its ESG (Environmental, Social, and Governance) practices, achieving an MSCI ESG rating upgrade to A [16][17]

白云山 2024 年年度股东大会 广州白云山医药集团股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 3 日 第 1 页 共 48 页 白云山 2024 年年度股东大会 | 目 | 录 | | --- | --- | | 一、会议须知…………………………………………………………3 | | | 二、会议议程…………………………………………………………5 | | | 三、会议议案…………………………………………………………7 | | 第 2 页 共 48 页 白云山 2024 年年度股东大会 广州白云山医药集团股份有限公司 2024 年年度股东大会会议须知 为了维护广州白云山医药集团股份有限公司（以下简称"广药白 云山"、"本公司"、"公司"）全体股东的合法权益，确保本公司 2024 年年度股东大会（以下简称"本次股东大会"或"年度股东大会"） 正常秩序和议事效率，保证本次股东大会的顺利进行，依据有关法律 法规、本公司《广州白云山医药集团股份有限公司章程》（以下简称 "《公司章程》"）及《广州白云山医药集团股份有限公司股东大会 议事规则》（以下简称"《股东大会议事规则》"）的有关规定，特 制订 ...

证券代码：600332 证券简称：白云山 公告编号：2025—042 广州白云山医药集团股份有限公司 关于子公司通过高新技术企业认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广西白云山盈康药业有限公司（以下简称"广西盈康"）已通 过高新技术企业重新认定，并收到由广西壮族自治区科学技术厅、广 西壮族自治区财政厅、国家税务总局广西壮族自治区税务局联合颁发 的《高新技术企业证书》，证书有关信息具体如下： 企业名称：广西白云山盈康药业有限公司 证书编号：GR202445000589 发证日期：2024年12月7日 有效期：三年 广西盈康通过高新技术企业认定后，根据国家的相关规定，自获 得高新技术企业认定后连续三年内（2024年、2025年和2026年）可享 受国家关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业 所得税。2024年本公司已按照15%的所得税税率计缴该公司所得税。 本次广西盈康获得《高新技术企业证书》不会对本公司当期经营业绩 产生重大 ...

Group 1 - Recent demand for home testing and antiviral medications has surged, with COVID-19 antigen search demand in Beijing, Shanghai, Guangzhou, and Shenzhen increasing by 3-5 times compared to the previous week [1] - Home testing service orders on Meituan have increased by 30% year-on-year over the past four days, while orders for COVID-related antiviral medications have more than doubled compared to the previous week [1] - Meituan Health has launched a special public welfare program in collaboration with Wanfang Biological and medical device merchants, allowing users to purchase COVID-19 antigen test kits for just one cent, targeting high-demand cities [1] Group 2 - Guangzhou Pharmaceutical Group's subsidiary, Baiyunshan and Huang Zhong Medicine, reports that current production capacity can meet market demand for antiviral drugs [2] - The company has collaborated with academic experts for over ten years, discovering that Banlangen has multi-target antiviral properties and can help regulate excessive immune responses [2] - The formulation of Kouyanqing granules, which includes various traditional Chinese medicinal ingredients, is effective in treating oral and throat diseases, potentially alleviating symptoms of pharyngitis [2]

Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].